• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Treace Announces Upcoming Board Chair Transition

    4/7/25 8:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email

    PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at the 2025 Annual Meeting of Stockholders, which is expected to occur on May 20, 2025. John T. Treace will continue to serve as Chief Executive Officer and will assume the role of Chairman of the Board immediately following the 2025 Annual Meeting of Stockholders. Richard W. Mott will continue to serve as the lead independent director.

    "It has been a privilege to serve as Chair of Treace's Board of Directors since the Company's inception in 2014," said James T. Treace. "We are excited about our expanded bunion portfolio and look forward to delivering additional innovations to address the evolving needs of our surgeon customers for the rest of 2025 and beyond, positioning us to drive further penetration in the bunion market. This is the right time to elevate new leadership to our Board to guide the Company during this next exciting chapter. John founded this Company and has extensive strategic, operational, and executive leadership experience as well as deep knowledge of the market, which will serve the Board, the Company, and our stockholders well. I have the utmost faith in his ability to continue to steward innovation and success at Treace."

    Mr. James T. Treace has served as the Founder and President of J&A Group, LLC, a privately funded medical device investment and consulting company since 2000. Before that, from 1996 to 1999, Mr. Treace served as Chief Executive Officer, President and Chairman of the Board of Xomed Surgical Products, Inc. until it was acquired by Medtronic plc. Prior to that, he served as Chief Executive Officer and Chairman of the Board of TreBay Medical Corp., an orthopaedic and microsurgical device company from 1993 to 1996. From 1981 to 1990 he served as President and Chief Executive Officer of Concept, Inc now known as Conmed Linvatec. Prior to that, Mr. Treace served as Executive Vice President of Richards Medical, now known as Smith & Nephew from 1966 to 1981. Mr. Treace previously served as Chairman of the Boards of Kyphon, Inc., now part of Medtronic plc, Wright Medical, acquired by Stryker Corporation, American Medical System, Inc., now part of Endo Pharmaceuticals and Keystone Dental, Inc.

    "I am honored to be appointed Chairman of the Board during this evolutionary time for the Company," said Mr. John T. Treace. "Jim's mentorship has been invaluable, and I know that I speak for the entire Board when I say that his unwavering service and dedication to the Company has been a meaningful part of its operational success. As we move into this next phase of leadership and growth at Treace, the entire Board and management team remain resolute in our commitment to creating exceptional value for our customers, stockholders and employees."

    Richard W. Mott, Lead Independent Director of Treace, stated, "I extend my heartfelt thanks to Jim for his generous dedication and service, and congratulate John on his well-deserved appointment as Chairman of the Treace Board. Over the last 11 years, John has been integral to our strategic evolution. He deeply understands our businesses and shares our passion for innovation, continuous improvement, and success."

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company's expectations regarding the Board chair transition, the delivery of additional innovations in 2025 and beyond and its further penetration in the bunion market. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace's public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 27, 2025. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

    About Treace Medical Concepts

    Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

    To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

    Contacts:

    Treace Medical Concepts, Inc.

    Mark L. Hair

    Chief Financial Officer

    [email protected]

    (904) 373-5940

    Investors:

    Gilmartin Group

    Vivian Cervantes

    [email protected]



    Primary Logo

    Get the next $TMCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    5/8/2024$15.00 → $6.00Buy → Hold
    Stifel
    5/8/2024$15.00 → $8.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TMCI
    Financials

    Live finance-specific insights

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec

      2/6/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Treace Medical Concepts upgraded by BTIG Research with a new price target

      BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

      2/4/25 7:10:07 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Treace Medical Concepts with a new price target

      Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50

      12/31/24 7:48:21 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Analyst resumed coverage on Treace Medical Concepts with a new price target

      Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00

      12/17/24 8:22:27 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    SEC Filings

    See more
    • SEC Form S-8 filed by Treace Medical Concepts Inc.

      S-8 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/9/25 8:43:56 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Treace Medical Concepts Inc.

      10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:10:24 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:05:29 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Innovation Officer Scanlan Sean F. exercised 50,000 shares at a strike of $1.05 and sold $398,460 worth of shares (50,000 units at $7.97) (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/19/25 9:30:04 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SVP, Sales Berutti Aaron covered exercise/tax liability with 2,543 shares, decreasing direct ownership by 1% to 209,999 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. covered exercise/tax liability with 7,084 shares, decreasing direct ownership by 0.10% to 6,789,106 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/14/24 3:38:23 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/12/24 6:01:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/8/24 3:44:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/4/25 6:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      9/17/24 5:17:19 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      8/19/24 9:00:08 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Upcoming Board Chair Transition

      PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at

      4/7/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Treace Appoints Guy Guglielmino as Chief Commercial Officer

      PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

      12/2/24 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

      PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

      8/21/23 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

      PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

      7/12/23 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care